Multicentre phase II pharmacological evaluation of rhizoxin

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1944-1948

  McLeod, H L ^a,i   Murray, L S ^a   Wanders, J ^b   Setanoians, A ^a   Graham, M A ^a   Pavlidis, N ^c   Heinrich, B ^d   Ten Bokkel Huinink, W W ^e   Wagener, D J Th ^f   Aamdal, S ^g   Verweij, J ^h  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF MUNICH   (Germany)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h ERASMUS MC CANCER INSTITUTE   (Netherlands)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Pharmacodynamics; Pharmacokinetics; Phase II trial; Rhizoxin

Indexed keywords

RHIZOXIN;

ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; PAIN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

EID: 8044245448     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.657     Document Type: Article

References (17)

1. BISSETT D, GRAHAM M, SETANOIANS A, CASSIDY J, KERR DJ, HENRAR R, MORRISON G AND KAYE SB. (1992). Phase 1 and pharmacokinetic study of rhizoxin. Cancer Res., 52, 2894-2898.
2. BOECKMAN AJ, SHEINER LB AND BEAL SL. (1992). NONMEM IV User's Guide, Parts I-VII. NONMEM Project Group, University of California: San Francisco, CA.
3. CASSIDY J AND MCLEOD HL. (1995). It is possible to design a logical development plan for an anti-cancer drug? Pharmaceut. Med., 9, 95-103.
4. GIANNI L, KEARNS CM, GIANI A, VIGANO L, LOCATELLI A, BONADONNA G AND EGORIN MJ. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J. Clin. Oncol., 13, 180-190.
5. GIBALDI M AND PERRIER D. (1982). Pharmacokinetics. 2nd edn. Dekker: New York.
6. GRAHAM MA, BISSETT D, SETANOIANS A, HAMILTON T, KERR DJ, HENRAR R AND KAYE SB. (1992). Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme. J. Natl Cancer Inst., 84, 494-500.
7. HANAUSKE AR, CATIMEL G, AAMDAL S, TEN BOKKEL HUININK W, PARIDAENS R, PAVLIDIS N, KAYE SB, TE VELDE A, WANDERS J AND VERWIEJ J FOR THE EORTC EARLY CLINICAL TRIALS GROUP. (1996), Phase II clinical trials with rhizoxin in breast cancer and melanoma. Br. J. Cancer, 73, 397-399.
8. HENDRIKS HR, PLOWMAN J, BERGER DP, PAULL KD, FIEBIG HH, FODSTAD O, DREEF-VAN DER MEULEN HC, HENRAR REC, PINEDO HM AND SCHWARTSMANN G. (1992). Preclinical antitumour activity and animal toxicity studies of rhizoxin, a novel tubulin-interacting agent. Ann. Oncol., 3, 755-763.
9. HUIZING MT, KEUNG ACF, ROSING H, VANDER KUIJ V, TEN BOKKEL HUININK WW, MANDJES IM, DUBBELMAN AC, PINEDO HM AND BEIJNEN JH. (1993). Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11, 2127-2135.
10. KAPLAN S, HANAUSKE AR, PAVLIDIS N, BRUNTSCH U, TE VELDE A, WANDERS J, HEINRICH B AND VERWEIJ J FOR THE EORTC EARLY CLINICAL TRIALS GROUP. (1996). Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br. J. Cancer, 73, 403-405.
11. MCLEOD HL, GRAHAM MA, AAMDAL S, SETANOIANS A, GROOT Y AND LUND B ON BEHALF OF THE EORTC EARLY CLINICAL TRIALS GROUP. (1996). Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. Eur. J. Cancer 32, 1518-1522.
12. ROWINSKY EK, DONEHOWER RC, JONES RJ AND TUCKER RW. (1988). Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48, 4093-4100.
13. SONNICHSEN DS, HURWITZ CA, PRATT CB, SHUSTER JJ AND RELLING MV. (1994). Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumours. J. Clin. Oncol., 12, 532-538.
14. SULLIVAN AS, PRASAD V, ROACH MC, TAKAHASHI M, IWASAKI S AND LUDEUNA RF. (1990). Interaction of rhizoxin with bovine brain tubulin. Cancer Res., 50, 4277-4280.
15. TSURUO T, OH-HARA T, LIDA H, TSUKAGOSHI S, SATO Z, MATSUDA I, IWASAKI S, OKUDA S, SHIMIZU F, SASAGAWA K, FUKAMI M, FUKUDA K AND ARAKAWA M. (1986). Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumour agent against human and murine tumour cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385.
16. VERWEIJ J, WANDERS J, GIL TH, SCHOFFSKI P, CATIMEL G, TE VELDE A AND DE MULDER PHM FOR THE EORTC EARLY CLINICAL TRIALS GROUP. (1996). Phase II study of rhizoxin in squamous cell head and neck cancer. Br. J. Cancer, 73, 400-402.
17. WILD MD, WALLE UK AND WALLE T. (1995). Extensive and saturable accumluation of paclitaxel by the human platelet. Cancer Chemother. Pharmacol., 36, 41-44.